Reduced Healthcare Resource Use in Patients With Chronic Insomnia After Treatment With a Digital Therapeutic With 2-Year Follow-Up


Forma F1, Knight T2, Baik R2, Wallace M3, Malone D4, Xiong X1, Mahon R1, Velez F1, Thorndike F1, Maricich Y1
1Pear Therapeutics (US), Inc., Boston, MA, USA, 2Labcorp Drug Development, Gaithersburg, MD, USA, 3Labcorp Drug Development, London, LON, UK, 4Strategic Therapeutics, LLC, Tucson, AZ, USA

OBJECTIVES: This analysis examined the impact of a prescription digital therapeutic (PDT) for treating chronic insomnia (Somryst®) on healthcare resource use (HCRU) by comparing patients treated with digital cognitive behavioral therapy for insomnia (dCBTi) to patients not treated with dCBTi, but with insomnia medications.

METHODS: A retrospective health claims data analysis was conducted in two cohorts across the United States: patients registered for dCBTi between 1 June 2016 and 31 October 2018 vs. patients not registered for dCBTi who received medication for insomnia (controls). Observation period was 16-24 months. Incidence rates for HCRU encounter type were calculated using a negative binomial model for both cohorts. Costs were estimated by multiplying HCRU by published average costs.

RESULTS: Evaluated were 248 dCBTi patients (median age 56.5 years, 57.3% female, 52.4% treated with sleep-related medications) and 248 matched controls (median age 55.0 years, 56.0% female, 100.0% treated with sleep-related medications). 24 months post-initiation, dCBTi patients had significantly lower incidence of hospitalizations (55% lower, IRR: 0.45; 95% CI: 0.28-0.73; P=0.001), emergency department (ED) visits (59% lower; IRR: 0.41; 95% CI: 0.27-0.63; P<0.001); and hospital outpatient visits (36% lower; IRR: 0.64; 95% CI: 0.49-0.82; P<0.001). Use of sleep medications was more than four times greater in controls vs. dCBTi patients, with 9.6 (95% CI: 7.88-11.76) and 2.4 (95% CI: 1.91-2.95) prescriptions/patient, respectively (P<0.001). All-cause per-patient HCRU costs were $8,202 lower over 24 months for dCBTi patients vs. controls. Number needed to treat (NNT) with dCBTi (instead of the control) for one additional patient to not have a hospitalization or an ED visit was 6.

CONCLUSIONS: Patients with chronic insomnia treated with a PDT delivering CBTi had durable real-world reductions in health care resource use compared to matched controls, with per-patient cost savings over 24 months of $8,202.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)




Economic Evaluation, Study Approaches


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now